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Human immunodeﬁciency virus (HIV)-1 infects approxi-
mately 33 million people worldwide and 40–70% of these
have associated complications in the CNS. The most severe
form of HIV-1-associated neurocognitive disorders (HAND)
is HIV-1-associated dementia (HAD); dementia associated
with reactive astrogliosis and neuronal dysfunction/death
(Lindl et al. 2010). While the advent of antiretroviral therapy
has transformed HIV-1 infection into a manageable, chronic
condition and lowered the incidence of HAD, the prevalence
of HAD has increased because of the extended life span of
HIV-1 infected individuals (Lindl et al. 2010). Here, we
investigate the expression of CCAAT enhancer-binding
protein (C/EBP) b during HIV-1 infection and its regulation
of astrocyte tissue inhibitor of metalloproteinase (TIMP)-1
production.
Astrocytes, important homeostatic regulators of the brain,
are activated during HAD and display an altered gene
expression proﬁle during neuroinﬂammation (Faulkner et al.
2004; Heales et al. 2004; Sofroniew 2005; Laird et al. 2008;
Yadav and Collman 2009; Sofroniew and Vinters 2010).
Although the cellular expression of TIMP-1 in the CNS
varies with disease state (La Fleur et al. 1996; Rivera et al.
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Abstract
Human immunodeficiency virus (HIV)-1-associated neuro-
cognitive disorders (HAND) associated with infection and
activation of mononuclear phagocytes (MP) in the brain, oc-
cur late in disease. Infected/activated MP initiate neuroin-
flammation activating glial cells and ultimately disrupting
neuronal function. Astrocytes secrete tissue inhibitor of me-
talloproteinase (TIMP)-1 in response to neural injury. Altered
TIMP-1 levels are implicated in several CNS diseases.
CCAAT enhancer-binding protein b (C/EBPb), a transcription
factor, is expressed in rodent brains in response to neuroin-
flammation, implicating it in Alzheimer’s, Parkinson’s, and
HAND. Here, we report that C/EBPb mRNA levels are ele-
vated and its isoforms differentially expressed in total brain
tissue lysates of HIV-1-infected and HIV-1 encephalitis pa-
tients. In vitro, HAND-relevant stimuli additively induce C/
EBPb nuclear expression in human astrocytes through
7 days of treatment. Over-expression of C/EBPb increases
TIMP-1 promoter activity, mRNA, and protein levels in human
astrocytes activated with interleukin-1b. Knockdown of C/
EBPb with siRNA decreases TIMP-1 mRNA and protein
levels. These data suggest that C/EBPb isoforms are in-
volved in complex regulation of astrocyte TIMP-1 production
during HIV-1 infection; however, further studies are required
to completely understand their role during disease progres-
sion.
Keywords: astrocyte and neuroinflammation, CCAAT en-
hancer-binding protein b, human immunodeficiency virus-1-
associated dementia, tissue inhibitor of metalloproteinase-1.
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1997; Bugno et al. 1999; Jaworski 2000), astrocytes are
major producers of this (Pagenstecher et al. 1998; Jaworski
2000; Suryadevara et al. 2003) physiological antagonist of
matrix metalloproteinases (MMPs) that stimulates cellular
proliferation and inhibits apoptosis (Hornebeck 2003;
Jourquin et al. 2005; Ould-yahoui et al. 2009). TIMP-1 is
a multifunctional molecule that may affect pathology in
multiple ways besides MMP inhibition, and this places an
impetus on understanding how astrocyte TIMP-1 expression
contributes to overall TIMP-1 levels during HAD. TIMP-1
expression levels are dysregulated in HAD and other CNS
pathologies (Gardner and Ghorpade 2003). Reduced TIMP-
1 expression in the CSF and brain tissues of HAD patients
was previously reported (Suryadevara et al. 2003), but the
mechanism causing this deﬁcit is unknown. In vitro,
astrocyte activation with the HIV-relevant stimulus, inter-
leukin (IL)-1b, was shown to initially increase TIMP-1
expression, which decreased with long-term stimulation
(Suryadevara et al. 2003). Although, the TIMP-1 : MMP
balance is implicated in several CNS pathologies (Yong
et al. 1998) and the TIMP-1 knockout mice showed
impaired learning and memory, the mechanism for this is
unknown and is likely multifaceted (Lorenzl et al. 2002,
2003, 2008; Hornebeck 2003; Chaillan et al. 2006). TIMP-
1 expression is well studied in several model systems, but
the distinct mechanisms controlling short-term versus long-
term regulation in astrocytes are incompletely understood.
The 1.7 kb sequence upstream of exon 1 and part of intron
1 contains numerous regulatory elements including ﬁve
CCAAT boxes (Clark et al. 1997; Phillips et al. 1999).
Several transcriptional regulators are known to be up-
regulated in astrocytes during neuroinﬂammation (Panenka
et al. 2001; Brambilla et al. 2005, 2009; Abraham et al.
2006; Gris et al. 2007; Chen et al. 2008; Herrmann et al.
2008; Sofroniew and Vinters 2010). Recently, it was reported
that the transcription factor C/EBPb is expressed in rodent
astrocytes in response to inﬂammatory stimuli (Albertini
et al. 1998; Ejarque-Ortiz et al. 2007) and is involved in
many cellular processes of the CNS (Alberini et al. 1994;
Sterneck and Johnson 1998; Yukawa et al. 1998; Cardinaux
et al. 2000; Menard et al. 2002; Cortes-Canteli et al. 2004;
Nadeau et al. 2005; Ejarque-Ortiz et al. 2007; Sandhir and
Berman 2010). Although, C/EBPb is a proliﬁc transcription
factor that is expressed in microglia and neurons (Sterneck
and Johnson 1998; Ejarque-Ortiz et al. 2007), it is unclear
what proportion each of these cell types contributes to C/
EBPb expression in the brain. It is likely that C/EBPb plays a
distinct role in regulating the response of each cell type
during neuroinﬂammation. However, astrocytes are well-
accepted major producers of brain TIMP-1, thus, in this
study, we focus on the role of C/EBPb in astrocytes
(Pagenstecher et al. 1998; Crocker et al. 2006). Alternative
start site initiation results in a single C/EBPb mRNA being
translated into three isoforms: 42, 40, and 20 kDa. The two
larger isoforms have transcriptional activation properties,
whereas the 20 kDa isoform is a transcriptional silencer
(Sears and Sealy 1994). C/EBPb functions by dimerizing
with other factors to regulate transcription (Sears and Sealy
1994). In this study, we hypothesize that C/EBPb is
expressed in astrocytes during HAND and contributes to
the initial increase in TIMP-1 production by astrocytes, and
possibly to the following dysregulation of TIMP-1 that we
reported from in vitro studies and clinical cases (Suryadevara
et al. 2003).
Here, we show that C/EBPb is differentially expressed in
the brains of HIV-1-infected (HIV+) and HIV encephalitis
(HIVE) brain specimens. We report that primary human
astrocytes express C/EBPb in response to HAND-relevant
stimuli and the transcription factor contributes to the complex
regulation of astrocyte TIMP-1. Overall, this work identiﬁes
C/EBPb as a transcription factor that contributes to astrocyte
TIMP-1 regulation and is expressed in the human brain
during HIV infection. These ﬁndings may have broader
implications in many other neuroinﬂammatory CNS pathol-
ogies.
Experimental procedures
Preparation of human brain lysates
Brain lysates were prepared from specimens obtained from the
NNTC, Center for Neurovirology and Neurodegenerative Disorders
brain bank and Rapid Autopsy Program at the University of
Nebraska Medical Center as previously described by Suryadevara
et al. (2003). Protein concentration was determined by bicionconic
acid method as suggested by the manufacturer (Pierce, Rockford, IL,
USA).
Isolation, cultivation, and activation of human astrocytes
Human astrocytes were isolated from ﬁrst- and early second-
trimester aborted specimens obtained from the Laboratory of
Developmental Biology, University of Washington, Seattle; in full
compliance with the ethical guidelines of the NIH, University of
Washington and University of North Texas Health Science Center.
Astrocytes were isolated from specimens as described by Gardner
et al. (2006). Astrocyte activation was achieved by stimulating with
IL-1b, tumor necrosis factor (TNF)-a, and/or HIV-1JR-FL for various
time periods. All treatment conditions were derived empirically
through testing a range of concentrations for maximal activation of
astrocytes. Astrocytes were treated with HIVJR-FL at 6000 counts
reverse transcriptase activity/mL/min and IL-1b was used at 20 ng/
mL. The concentrations used were in the range described in the
current literature (Liu et al. 1996; Suryadevara et al. 2003; Dhar
et al. 2006; Gardner et al. 2006). Furthermore, an in vivo correlate,
mouse models utilizing adenovirus-driven IL-1b over-expression in
the brain, achieved expression levels around 10 ng/mg total protein
7 days post-injection (Ferrari et al. 2006) or a mean of 41 ng in the
whole striatum 8 days post-injection (Ferrari et al. 2004), respec-
tively. During prolonged activation, cells received a medium
exchange every 4 days with the original treatment concentrations.
De novo TIMP-1 synthesis was measured in activated astrocytes by
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blocking translation with 10 lg/mL cycloheximide (Sigma Chem-
icals, St. Louis, MO, USA) for 2, 8, and 24 h. Data presented are
representative of a minimum of three independent experiments with
two or more independent donors.
RNA isolation and real time PCR (RT2PCR)
RNA from activated astrocytes was extracted (Qiagen, Alameda,
CA, USA) and reverse transcribed into cDNA as per the
manufacturer’s instructions (PE Applied Biosystems, Inc., Foster
City, CA, USA). TaqMan 5¢ nuclease RT2 PCR assays were
performed using an ABI Prism 7500 sequence-detection system (PE
Applied Biosystems, Inc.). The following TaqMan Gene Expression
Assay primers were used: TIMP-1 (C/N: Hs99999139_m1), C/
EBPb (C/N: Hs00270923_s1), and glyceraldehyde-phosphate dehy-
drogenase (C/N: 4310859). The reactions were carried out at 48C
for 30 min, 95C for 10 min, followed by 40 cycles of 95C for 15 s
and 60C for 1 min. Samples were analyzed in triplicate. All
experiments and analyses meet the minimum standard guidelines for
ﬂuorescence-based RT2PCR experiment. One-way analysis of
variance (ANOVA) was used to analyze RT2PCR data.
Western blot
Astrocytes were cultured as adherent monolayers in 75 cm2 ﬂasks at
a density of 8 · 106 cells per ﬂask. The following day, cells were
treated with IL-1b (20 ng/mL). Cells were lysed, and nuclear
extracts were isolated at 72 and 168 h post-IL-1b treatment using
nuclear extraction reagent (Fisher, Waltham, MA, USA). Equal
amounts of protein (30 lg/lane from astrocytes and 160 lg/lane
from brain lysates) were resolved by 12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis and subsequently transferred to a
nitrocellulose membrane using i-Blot (Invitrogen, Carlsbad, CA,
USA). The membrane was incubated with anti-C/EBPb (Santa Cruz
Biotechnology, Santa Cruz, CA, USA; C/N : C-19 at a dilution of
1 : 200 for astrocyte lysates and 1 : 40 for brain lysates), and then in
secondary antibody at a concentration of 1 : 5000. b-actin was used
as a loading control.
Measurement of TIMP-1 protein and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) levels
TIMP-1 levels in astrocyte supernatants were measured using a
commercially available ELISA kit (R&D Systems, Minneapolis,
MN, USA). The MTT assay was performed at appropriate time
points according to the method originally described by Manthrope
et al. (1986). The ELISA determinations yielded quantities of
protein in units of ng/mL, and were normalized to MTT values.
Results were analyzed with GraphPad Prism 4.0 (GraphPad
Software, Inc., La Jolla, CA, USA) using one-way ANOVA with
Newman–Keul’s post-test for multiple comparisons.
TIMP-1 promoter constructs and C/EBPb-expressing plasmids
A TIMP-1 promoter-driven ﬁreﬂy luciferase (pTIMP-1-luc) con-
struct was used to measure TIMP-1 promoter activity in transfected
astrocytes. The )1718/+988 portion of the TIMP-1 sequence was
cloned into the pGL3-Basic reporter vector (Promega, Madison, WI,
USA) and kindly provided by Dr Ian Clark at the University of East
Anglia, UK (Clark et al. 1997). The wild-type (WT) C/EBPb-
expressing plasmid expresses the 42, 40, and 20 kDa isoforms,
whereas the mutated plasmid has a mutation in the 3¢-translation
start sites and predominantly expresses the 42 kDa isoform.
Dr Calkhoven kindly provided the C/EBPb-expressing plasmids
from Leibniz Institute for Age Research, Fritz Lipman Institute in
Germany.
Transfection of primary human astrocytes with luciferase reporter
constructs
Astrocytes were cultured as adherent monolayers in a 48-well plate
at a density of 0.15 · 106 cells/well. The following day, cells were
transfected with 1.5 lg of total DNA. Total DNA consisted of a
mixture of the pTIMP-1-luc and the simian vacuolating virus
promoter-driven Renilla luciferase (Promega) plasmids with or
without C/EBPb-expressing plasmids, or a control plasmid (CP). We
used lipofectamine reagent to transfect the plasmid as per the
manufacturer’s instructions (Invitrogen). Untreated and mock-
transfected controls were maintained for comparison. Mock controls
were transfected without plasmid. At 2 days post-transfection
promoter activity was measured as luciferase activity in cell extracts
using the Dual-Glo Luciferase Assay System as per the manufac-
turer’s instructions (Promega). Luciferase activity was determined as
a ratio of ﬁreﬂy to Renilla luciferase using the Tecan Inﬁnite Pro 200
luminometer (Tecan, Mannedorf, Switzerland). Renilla luciferase
activity was thus used as an internal control. All data were analyzed
with GraphPad Prism 4.0 in triplicate using one-way ANOVA with
Newman–Keul’s post-test for multiple comparisons unless other-
wise speciﬁed. Data presented are representative of a minimum of
three independent experiments with two or more independent
donors.
Transfection of primary human astrocytes with siRNA
Astrocytes were resuspended in nucleofector transfection reagent
(Lonza, Walkersville, MD, USA) at a concentration of 80 · 106
cells/mL and transfected with short interfering (si) C/EBPb
(GGCCCUGAGUAAUCGCUUA – 100 nM) or non-speciﬁc control
short interfering RNA (siCON; Dharmacon, Lafayette, CO, USA) as
per the manufacturer’s instructions. Cells were then cultured in
25 cm2 ﬂasks and allowed to recover for 24 h prior to treatment
with IL-1b (20 ng/mL).
Statistical analyses
Statistical analyses were carried out using GraphPad Prism 4.0
software, with one-way ANOVA and Newman–Keuls post-test for
multiple comparisons. Signiﬁcance was set at p < 0.05 and data
represent mean values ± SEM. Data presented are representative of
a minimum of three independent experiments with two or more
independent donors.
Results
C/EBPb and TIMP-1 expression in HIV-1-infected
individuals
C/EBPb is a proliﬁc transcription factor that regulates gene
expression during inﬂammation (Alberini et al. 1994; Ster-
neck and Johnson 1998; Yukawa et al. 1998; Cardinaux
et al. 2000; Menard et al. 2002; Cortes-Canteli et al. 2004;
Nadeau et al. 2005; Ejarque-Ortiz et al. 2007; Sandhir and
Berman 2010). To determine C/EBPb expression patterns in
 2011 The Authors
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the brain of HIV-1-infected patients, we performed RT2PCR
(n = 14) and western blotting (n = 8) using total brain tissue
lysates from the frontal cortex of control, HIV+, and HIVE
patients (Table S1). The control samples used for RT2PCR
were made up of four females and two males (age: 37–52); of
the HIV-infected patients, seven were male and one was
female (25–55), and all had progressed to AIDS. Of the
AIDS patients, four showed signs of encephalitis and the
remaining four showed no signs of CNS pathology. There
were no detectable signs of opportunistic infection in the
CNS of any patients studied. C/EBPb mRNA levels were
signiﬁcantly higher in HIV+ patients compared with HIVE
and control patients (Fig. 1a). Low levels C/EBPb mRNA
and protein were detected in the brain tissues from the
control patients. All HIV-1-infected patients showed expres-
sion of at least one isoform of C/EBPb. C/EBPb was detected
in the brain lysates of three HIV+ patients, in which we
detected a 42 kDa isoform and an unreported band around
25 kDa (Fig. 1b). The 20 kDa isoform was detected in two
brain lysates from HIVE patients. Overall, this work shows
that C/EBPb expression is markedly increased in the brains
of these HIV-1-infected individuals compared with unin-
fected controls, C/EBPb mRNA, and protein levels are lower
in the brain tissues of HIVE compared with HIV+ patients.
Furthermore, the expression pattern of C/EBPb isoforms
varies between HIV+ and HIVE patients. A 42 kDa isoform
and an unreported band at 25 kDa were detected in HIV+
tissues, whereas a 20 kDa isoform was detected in HIVE
patients.
HIV-relevant stimuli induce C/EBPb expression in human
astrocytes
Cultured human astrocytes were used to determine if HIV-
relevant stimuli induce C/EBPb expression. We treated
astrocytes with IL-1b (20 ng/mL) for days 1, 3, and 7, and
then collected total RNA and protein (Fig. 2a and b). C/
EBPb mRNA was signiﬁcantly (p < 0.001) increased in IL-
1b-treated astrocytes compared with untreated controls at all
time points. C/EBPb mRNAwas increased 1.4-fold in IL-1b-
treated astrocytes at day 3 (p < 0.01) and increased 2.5-fold
further at day 7 (***p < 0.001), (Fig. 2a). Normalized
levels of C/EBPb mRNA in control astrocytes were not
signiﬁcantly different at any time-point. We performed
immunoblotting for C/EBPb in days 3 and 7 nuclear extracts
from IL-1b-treated astrocytes as described in the ‘Experi-
mental procedures’ (Fig. 2b). C/EBPb levels were increased
in IL-1b-treated astrocytes compared with untreated controls
at days 3 and 7. To determine if HAND-relevant stimuli,
other than IL-1b, are capable of inducing C/EBPb expres-
sion, we treated astrocytes with HIVJR-FL (6000 counts RT
activity/mL/min), IL-1b (20 ng/mL), and TNF-a (20 ng/
mL), alone, or in combination for 1 and 3 days (Fig. 2c). IL-
1b and TNF-a both induced increases in C/EBPb mRNA
compared with control, and led to a further increase through
day 3 of stimulation. Treatment with HIVJR-FL enhanced the
IL-1b- and TNF-a-mediated increase in C/EBPb mRNA.
Treatment with TNF-a or HIVJR-FL alone had no signiﬁcant
effect on C/EBPb mRNA levels at day 1, but resulted in a
twofold (p < 0.01) increase in at day 3 compared with
untreated controls. HIVJR-FL combined with TNF-a further
enhanced the induction of C/EBPb mRNA to threefold,
compared with untreated controls at day 3. Treatment with
IL-1b signiﬁcantly (p < 0.001) increased C/EBPb mRNA
levels at days 1 and 3 compared with untreated controls. We
isolated protein from HIV-relevant stimuli-treated astrocytes
2 days post-treatment, and performed western blot for C/
EBPb (Fig. 2d). Protein levels were markedly increased in
IL-1b-, TNF-a-, IL-1b + TNF-a-, and HIVJR-FL + IL-
1b + TNF-a-treated astrocytes compared with untreated
controls. Treatment with TNF-a alone had less effect than
Fig. 1 CCAAT enhancer-binding protein b (C/EBPb) mRNA levels are
elevated in the brain tissues from HIV+ patients. C/EBPb 42 kDa and
20 kDa isoforms are detectable in brain lysates of HIV+ and HIVE
patients. Total RNA isolated from brains of control, HIV+, and HIVE
patients was reverse transcribed to cDNA and subjected to RT2PCR
for C/EBPb and TIMP-1. (a) C/EBPb mRNA levels were significantly
(***p < 0.001) higher in samples from HIV+ patients compared with
control or HIVE patients. (b) Low levels of the 42 kDa isoform were
detected in lysates from control patients whereas increased 42 kDa, a
light band at 20 kDa, and a strong band at 25 kDa was detected in all
samples from HIV+ patients.
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IL-1b alone, and combinations IL-1b + TNF-a and HIVJR-
FL + IL-1b + TNF-a resulted in the most robust increase in
C/EBPb protein expression. Taken together, both C/EBPb
mRNA and protein levels are robustly increased in response
to HIV-relevant stimuli.
We treated astrocytes with IL-1b for 48 h, ﬁxed and co-
localized glial ﬁbrillary acidic protein (GFAP) as an astro-
cyte-speciﬁc marker (red) with C/EBPb (green) in activated
human astrocytes (Fig. 3b). In control cells, GFAP is present
throughout the cell body of the astrocytes. Control astrocytes
have a larger cell body, (Fig. 3a), whereas activated astro-
cytes have extensive processes protruding from their soma
and more dense staining of GFAP (Fig. 3b and c). Low levels
of C/EBPb are present in the nuclei of control human
astrocytes compared with activated astrocytes, where the
green signal from the nuclei is markedly enhanced. Together
with the mRNA and protein expression data represented
earlier, this conﬁrms that C/EBPb expression is increased
and localized to the nucleus of astrocytes in response to
HAND-relevant stimuli.
TIMP-1 production de novo
Prior to verifying the speciﬁc effects of C/EBPb on TIMP-1
promoter regulation, we ﬁrst evaluated whether TIMP-1 is
synthesized de novo or instead released from intracellular
stores upon activation. Human astrocytes were treated with
translation inhibitor, cycloheximide at 10 lg/mL in conjunc-
tion with 20 ng/mL IL-1b for 2, 8, or 24 h (Fig. 4). TIMP-1
levels normalized to MTT units demonstrated that cyclohex-
imide signiﬁcantly inhibited TIMP-1 production following 8
and 24 h of IL-1b activation (***p < 0.001). These data
show that protein synthesis is necessary for TIMP-1 up-
regulation in acutely activated astrocytes and that TIMP-1 is
synthesized de novo in astrocytes. Hence, regulation of
mRNA transcription may serve as a promising target to
increase expression.
Fig. 2 HIV-1-associated neurocognitive disorders (HAND)-relevant
stimuli induce CCAAT enhancer-binding protein b (C/EBPb) expres-
sion induced in human astrocytes. (a) C/EBPb transcripts were
measured in mRNA isolated from primary human astrocytes treated
with IL-1b (20 ng/mL) for 1, 3, or 7 days. C/EBPb mRNA expression
was significantly increased compared with untreated at 1, 3, and
7 days (***p < 0.001). C/EBPb mRNA continued to increase, as
levels at 3 days were significantly higher than at 1 (**p < 0.01) and
levels at 7 days were significantly higher than at 3 (***p < 0.001). (b)
C/EBPb protein levels were assayed by immunoblotting. C/EBPb
protein levels were increased compared with untreated controls at 3
and 7 days. (c) C/EBPb transcripts were measured in total RNA
isolated from primary human astrocytes treated with IL-1b (20 ng/
mL), tumor necrosis factor (TNF)-a (20 ng/mL), and/or HIVJR-FL
(6000 counts RT activity/mL/min) for 1 or 3 days. C/EBPb mRNA
expression was significantly increased compared with untreated
control at 1 and 3 days in IL-1b- and TNF-a-treated astrocytes
(***p < 0.001). (d) Primary human astrocytes were treated with IL-1b
(20 ng/mL), TNF-a (20 ng/mL), and/or HIVJR-FL (6000 counts RT
activity/mL/min) for 2 days and then cell lysate was immunoblotted
for C/EBPb. C/EBPb protein levels were increased compared with
untreated controls in all samples. Data represent mean values ±
SEM in at least three independent experiments in at least two
independent donors.
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C/EBPb over-expression increases TIMP-1 promoter
activity, mRNA, and protein levels
We used a panel of plasmids that over-express C/EBPb
isoforms, in combination with luciferase-expressing plasmids
driven by the TIMP-1 promoter (Fig. 5a). Two C/EBPb over-
expression plasmids were used. The WT with three transla-
tion start sites leading to the production of three isoforms of
C/EBPb (42, 40, and 20 kDa), and the mutant plasmid in
which the two 3¢-translation start sites are mutated to allow
for predominant expression of the 42 kDa isoform. The
)1718/+988 region of the TIMP-1 promoter was used to
drive expression of the ﬁreﬂy luciferase gene. The )1718/
+988 region contains ﬁve CCAAT sites possibly involved in
promoter activity (Clark et al. 1997). We transfected human
astrocytes, by nucleofection and isolated nuclear extracts
48 h post recovery. We resolved nuclear extracts from
primary human astrocytes transfected with WT (lane 1) and
mutant (lane 2) plasmids, and performed western blot for C/
EBPb (Fig. 5b). Bands for all three isoforms were detected in
the astrocytes transfected with WT, whereas the mutant
transfected astrocytes expressed predominantly the 42 kDa
isoform. Next, we cotransfected astrocytes with pTIMP-1-luc
()1718/+988) and CP, WT, or mutant plasmids (Fig. 5c).
Cotransfection with the WT or mutant plasmids signiﬁcantly
increased activity from the )1718/+988 region of the TIMP-
1 promoter 2.6- and 3.0-fold, respectively, compared with
cotransfection with CP (***p < 0.001). Overall, over-expres-
sion of C/EBPb in primary human astrocytes signiﬁcantly
increases TIMP-1 promoter activity.
We transfected human astrocytes with C/EBPb WT or CP
by nucleofection, and activated with IL-1b for 24 h to
determine if over-expressing C/EBPb would increase the
initial astrocyte TIMP-1 response. Maximum C/EBPb over-
expression was achieved between 24 and 48 h post-trans-
fection in time course studies. We collected supernatant and
RNA 1-day post-treatment (Fig. 6a and b). IL-1b treatment
signiﬁcantly increased (***p < 0.001) TIMP-1 mRNA com-
pared with untreated cells. Over-expressing C/EBPb signif-
icantly increased TIMP-1 mRNA 1.4-fold compared with the
CP-transfected astrocytes with IL-1b treatment (***p <
0.001) (Fig. 6a). Over-expressing C/EBPb increased
(***p < 0.001) TIMP-1 secretion from activated astrocytes
by 1.5-fold compared with CP-transfected-activated astro-
cytes. These data conﬁrm that over-expressing C/EBPb
enhances TIMP-1 production in response to IL-1b (Fig. 6b).
C/EBPb knockdown decreases TIMP-1 mRNA and protein
expression
C/EBPb-speciﬁc short interfering RNA (siC/EBPb) was used
to evaluate the effect of C/EBPb knockdown on TIMP-1
mRNA and protein levels in activated astrocytes (Fig. 7). We
achieved 65% knockdown (***p < 0.001) of C/EBPbmRNA
through 72 h in astrocytes transfected with siC/EBPb, com-
pared with mock-transfected cells (Fig. 7a). We isolated
nuclear extracts from astrocytes transfected with siC/EBPb,
siCON, and mock 4 days post-transfection, and found
undetectable C/EBPb levels in siC/EBPb-transfected astro-
cytes compared with siCON-transfected cells (Fig. 7b).
Analysis of total RNA from siC/EBPb-transfected astrocytes
showed signiﬁcant down-regulation in TIMP-1 mRNA
(**p < 0.01) compared with siCON- or mock-transfected
cells (Fig. 7c). TIMP-1 levels supernatants from siC/EBPb-
transfected astrocytes were signiﬁcantly lower (*p < 0.05)
than those from siCON- or mock-transfected cells (Fig. 7d).
(a)
(b)
(c)
Fig. 3 CCAAT enhancer-binding protein b (C/EBPb) localizes to the
nucleus in response to IL-1b. (a) Untreated astrocytes were stained for
glial fibrillary acidic protein (GFAP) (red) and C/EBPb (green). Red
signal is detected throughout the cytoplasm and green is localized to
the nucleus. (b) In IL-1b-treated astrocytes C/EBPb (green) is local-
ized to the nucleus and demonstrates greater intensity as compared
with control astrocytes. (c) 4¢,6¢-diamidino-2-phenylindole staining in
IL-1b-treated astrocytes. All pictures were taken at 200· and data
represent at least three independent experiments in at least two
independent donors.
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Human astrocytes transfected with siC/EBPb expressed
approximately 30% less TIMP-1 mRNA and protein com-
pared with siCON-transfected astrocytes. These data illustrate
that knockdown of C/EBPb by siRNA results in down-
regulation of astrocyte TIMP-1 at the mRNA and protein
levels.
Discussion
Antiretroviral therapy has transformed HIV-1-infection into a
chronic-manageable illness in the industrialized world;
however, HAND represents a group of complications that
are increasingly prevalent and require continued investiga-
tion (Yadav and Collman 2009). Focus is shifting from the
dysfunctional neurons to glia as an important contributing
factor to neuroinﬂammation and to pathologies of the CNS
like HAND. Here, we focus on astrocytes, the most abundant
cells in the CNS, and their production of TIMP-1 in
response to injury. Previously, we reported that TIMP-1
production is dysregulated in HIV-infected brain specimens,
and in vitro experiments showed astrocytes up-regulate
TIMP-1 when acutely activated with IL-1b; however, long-
term IL-1b exposure was shown to down-regulate TIMP-1
production (Suryadevara et al. 2003; Gardner et al. 2006).
In these studies, we sought to delineate the mechanism of
astrocyte TIMP-1 dysregulation in the HIV-infected brain.
We report that total C/EBPb mRNA and protein levels are
higher in the brains of HIV+ patients compared with control
Fig. 4 De novo synthesis of astrocyte tissue inhibitor of metallopro-
teinase (TIMP)-1. Cycloheximide at 10 lg/mL was applied to astro-
cytes in conjunction with 20 ng/mL IL-1b for 2, 8, or 24 h. TIMP-1
levels in astrocyte supernatants were measured by ELISA and nor-
malized to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) activity. Cycloheximide significantly inhibited TIMP-1
production following 8 and 24 h of IL-1b activation, (***p < 0.001)
compared with untreated controls. Data represent mean val-
ues ± SEM of TIMP-1 protein levels determined in duplicate, in at least
three independent experiments and two independent donors.
Fig. 5 Over-expression of CCAAT enhancer-binding protein b (C/
EBPb) wild-type (WT) and mutant C/EBPb increases tissue inhibitor of
metalloproteinase (TIMP)-1 promoter activity. (a) Constructs used. (b)
Primary human astrocytes were transfected with WT or mutant by
nucleofection or Lipofectamine. WT expresses the C/EBPbmRNA that
has three translation start sites; generating two large (42 and 40 kDa)
isoforms from the first two start sites and one smaller 20 kDa isoform
from the most 3¢-start site. The mutant has a mutation in the two 3¢-
translation start sites, and predominately generates the 42 kDa iso-
form. (c) Cotransfection with WT or 42 kDa with pTIMP-1-luc ()1718/
+988) significantly (**p < 0.01 and ***p < 0.001, respectively) in-
creased activity. Data represent mean values ± SEM of luciferase
activity in triplicate, in at least three independent experiments and at
least two independent donors.
 2011 The Authors
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individuals. Conﬁrming similar results from rodent models,
HAND-relevant stimuli is shown to induce C/EBPb nuclear
expression in human astrocytes, and this response is
enhanced by co-stimulation with HIVJR-FL. Lastly, over-
expression of C/EBPb increases TIMP-1 production,
whereas knockdown of C/EBPb decreases TIMP-1 produc-
tion in human astrocytes in response to the HAND-relevant
stimulus, IL-1b.
Astrocytes react to neural injury by changing gene
expression that in turn leads to changes in cellular function,
morphology, and replication (Sofroniew and Vinters 2010).
C/EBPb regulates inﬂammatory responses in multiple cell
Fig. 7 Knockdown of CCAAT enhancer-binding protein b (C/EBPb)
with siRNA decreases tissue inhibitor of metalloproteinase (TIMP)-1
expression. C/EBPb mRNA was measured in primary human astro-
cytes 3 days after transfection with siC/EBPb or non-specific control
short interfering RNA (siCON) by nucleofection. (a) C/EBPb mRNA
expression was significantly (***p < 0.001) decreased in untreated
and IL-1b-treated astrocytes. (b) Four days after transfection, cell
lysates were immunoblotted for C/EBPb. C/EBPb protein was de-
tected in siCON-transfected astrocytes, but not in those transfected
with siC/EBPb. (c) TIMP-1 mRNA expression was significantly
decreased (**p < 0.01) at 3 days in astrocytes transfected with siC/
EBPb compared with mock or siCON-transfected astrocytes. (d)
TIMP-1 was measured using ELISA 3 days post-transfection.
Supernatant from astrocytes transfected with siC/EBPb had signifi-
cantly less (*p < 0.05) TIMP-1 protein than controls. Data represent
mean values ± SEM of TIMP-1 mRNA and protein levels determined
in duplicate, in at least three independent experiments and two
independent donors.
Fig. 6 Over-expression of wild-type (WT) CCAAT enhancer-binding
protein b (C/EBPb) increases tissue inhibitor of metalloproteinase
(TIMP)-1 expression. Astrocytes were transfected with plasmids over-
expressing WT or CP nucleofection, treated with IL-1b and total
mRNA, and supernatant was collected 48 h post-transfection. (a)
TIMP-1 mRNA levels were significantly (***p < 0.001) increased in
astrocytes transfected with WT as compared with CP-transfected
cells. Data represent mean values ± SEM of TIMP-1 mRNA levels
determined in triplicate in at least three independent experiments and
two independent donors. (b) TIMP-1 protein levels were significantly
(***p < 0.001) increased in the supernatant of astrocytes transfected
with WT as compared with CP-transfected cells. Data represent mean
values ± SEM of TIMP-1 levels determined in duplicate, in at least
three independent experiments and two independent donors.
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types (Akira et al. 1990) through promoter regulation; the
TIMP-1 promoter harbors ﬁve sequences predicted to bind C/
EBPb. Therefore, we focused on characterizing C/EBPb
expression in the brain during HIV-1 infection and its
involvement in injury-response and astrocyte TIMP-1 pro-
duction. As C/EBPb is highly expressed in glia during
inﬂammation (Alberini et al. 1994; Sterneck and Johnson
1998; Yukawa et al. 1998; Cardinaux et al. 2000; Menard
et al. 2002; Cortes-Canteli et al. 2004; Nadeau et al. 2005;
Ejarque-Ortiz et al. 2007; Sandhir and Berman 2010), it was
exciting to detect C/EBPb up-regulation at the mRNA and
protein level in HIV-1-infected brain specimens. Our ﬁnding
that C/EBPb mRNA and protein levels were highest in HIV+
brains and higher in HIVE than control brains suggests that
C/EBPb may be involved in the initiation of neuroinﬂam-
mation following HIV-1 infection rather than a consequence
of it. However, our data are derived from total brain tissue
lysates, thus, the source of C/EBPb in these brain tissue
specimens likely represents expression by cells other than
astrocytes as well. The presence of transcription-activating C/
EBPb isoforms in HIV patients versus the expression of the
20 kDa isoform detected in HIVE patients could represent a
switch that contributes to TIMP-1 dysregulation during
HAD. Low expression of the 42 kDa isoform of C/EBPb
was detected in control patients, and mRNA levels were
minimal.
It is established that human astrocytes are morphologically
and functionally more complex than their counterparts in
rodents; therefore, we aimed to conﬁrm that the C/EBPb
response is conserved in human astrocytes following activa-
tion with HAND-relevant stimuli (Oberheim et al. 2009). To
our knowledge, this is the ﬁrst report of C/EBPb expression
in primary human astrocytes in response to IL-1b. Interest-
ingly, C/EBPb expression showed a signiﬁcantly augmented
increase when co-stimulated with HIV-1JR-FL, and other
HAND-relevant stimuli. This phenomenon, however,
requires further investigation. C/EBPb expression continues
to rise through 7 days of stimulation, which suggests a
prolonged contribution to changes in astrocyte gene expres-
sion during inﬂammation. Along with other reports, this
study supports the idea that C/EBPb could be an integral part
of the regulatory mechanism in a general glial response to
neuroinﬂammation (Alberini et al. 1994; Sterneck and
Johnson 1998; Yukawa et al. 1998; Cardinaux et al. 2000;
Menard et al. 2002; Cortes-Canteli et al. 2004; Nadeau et al.
2005; Ejarque-Ortiz et al. 2007; Sandhir and Berman 2010).
We focused on IL-1b stimulation of human astrocytes for the
remainder of the studies, as it is a prototypical inﬂammatory
cytokine associated with HAND.
In our previous studies, we identiﬁed a robust increase in
astrocyte TIMP-1 mRNA and protein production response to
HAND-relevant stimuli (Gardner et al. 2006). Here, we
show that TIMP-1 is produced de novo upon stimulation with
HAND-relevant stimuli rather than released from intracellu-
lar stores. This suggests that transcriptional regulation may
be a promising therapeutic target to enhance astrocyte TIMP-
1 production. Regulation of TIMP-1 through the promoter
has been studied and is very complex (Clark et al. 1997;
Dean and Clark 1999; Dean et al. 2000; Fassina et al. 2000).
Among other elements, the TIMP-1 promoter harbors ﬁve C/
EBPb-binding sites (Clark et al. 1997). As we predicted,
over-expression of WT C/EBPb enhanced TIMP-1 promoter
activity, and over-expression of the 42 kDa isoform alone
showed further enhancement. This could be explained by the
transcriptional silencing activity of the 20 kDa isoform.
Over-expression of C/EBPb increased TIMP-1 promoter
activity, mRNA, and protein expression in human astrocytes
treated with the HAND-relevant stimulus, IL-1b. Knock-
down of C/EBPb resulted in the opposite effect on TIMP-1
expression; decreasing mRNA and protein levels in response
to IL-1b activation. Overall, these studies suggest that C/
EBPb contributes to regulating TIMP-1 production in
activated astrocytes. Thus, identifying TIMP-1 as one of
genes regulated by C/EBPb may provide a target for
increasing TIMP-1 expression during neuroinﬂammation. It
is noteworthy that C/EBPb knockdown did not completely
ablate TIMP-1 production in response to IL-1b, however,
over-expression of C/EBPb did enhance TIMP-1 production.
These data support the hypothesis that C/EBPb binds to
some or all of the ﬁve CCAAT sites in the TIMP-1 promoter
to regulate transcription, but this is most likely not the sole
factor inﬂuencing transcription. It is possible that C/EBPb
regulates the transcription of other factors that inﬂuence
TIMP-1 expression. Additional studies are necessary to
determine other contributors for TIMP-1 transcription, to
identify C/EBPb-binding partners and the precise binding
site for C/EBPb in the TIMP-1 promoter.
Neuroinﬂammation contributes to HAND, but the precise
mechanism required to transition from activated and
infected glia in the brain to dysfunctional neurons, is not
fully understood (Borjabad et al. 2009; Yadav and Collman
2009). Here, we show that HIV-1-infected patients, not yet
suffering from cognitive deﬁcits or any CNS pathology,
express C/EBPb known to mediate inﬂammatory responses.
C/EBPb detected in control patients is very low. Patients
with signs of cognitive deﬁcits or CNS pathology also
express C/EBPb; although they show different pattern of
isoform expression. This links observations about C/EBPb
to HIV infection of the CNS, and, most importantly, to
pathology in humans. However, neurons and microglia also
express C/EBPb. Previously, we reported decreased TIMP-1
protein in the CSF and brain of HIV and HIVE compared
with control patients (Suryadevara et al. 2003). Taken
together with the C/EBPb isoforms detected in the eight
patient samples, a shift in C/EBPb isoform expression
may contribute to dysregulation of TIMP-1 during HIV-1
infection. Further studies, using a large and well-characterized
cohort of patient samples, will be useful in determining if
 2011 The Authors
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the different C/EBPb isoforms are expressed at different
stages of HIV infection, the cell types in which they are
expressed, if this contributes to dysregulation of TIMP-1
during disease, and if the unidentiﬁed 25 kDa isoform
plays a role. There is no evidence, in the literature or our
studies, that C/EBPb or TIMP-1 expression is inﬂuenced
by gender.
Exciting new ﬁndings are revealing alternative roles for
secreted TIMP-1 as essential for maintaining homeostasis by
altering extracellular matrix architecture and acting as a
growth factor (Hornebeck 2003; Jourquin et al. 2005; Ould-
yahoui et al. 2009). These new ﬁndings support a need for
studies that culminate in the understanding of the mechanisms
regulating this tightly controlled gene. TIMP-1 promoter
regulation has been extensively studied, however, little is
known about the regulation of astrocyte TIMP-1 (Clark et al.
1997). This study opens the door to discovering additional
functions for C/EBPb in the CNS as well as another
mechanism potentially regulating astrocyte TIMP-1 produc-
tion during neuroinﬂammation. Further studies are needed to
delineate the roles of C/EBPb in the CNS, and the regulation
of TIMP-1 during neuroinﬂammation.
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